Annual results of the Galenica Group 2021

Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 8 March 2022

Galenica achieves record results and is going strengthened into the future.

The Galenica Group can look back on an extremely successful 2021 financial year. Galenica achieved record results with an increase in sales of 10.2% to CHF 3,834.7 million and an increase in adjusted1 EBIT of 26.4% to CHF 213.1 million. The Board of Directors wants the shareholders to benefit from this success and will propose a dividend increase of 17% (CHF 2.10 per share, of which CHF 1.05 will be paid from the capital contribution reserve) to the General Meeting. The record result was achieved thanks to the extraordinary commitment of all of Galenica’s employees. In recognition of their outstanding performance, all employees are to receive an extraordinary success bonus of CHF 1,000.

The strong earnings growth was driven in particular by extraordinary additional sales in relation to COVID-19. In addition, Galenica has grown successfully in the «Pharmacies at Home» sector as well as with new acquisitions and has gained further market shares in the physicians segment. EBIT growth also includes the profit from the sale of the property at the Galenica headquarters in Bern.

Despite major challenges posed by yet another year of the pandemic, Galenica has made considerable progress in implementing its strategic programmes and is going strengthened into the future.

Highlights of the 2021 financial year

  • In 2021, Galenica Group pharmacies carried out over 230,000 antigen, PCR and antibody tests and over 90,000 vaccinations.
  • With 28 primary care offerings, the pharmacy has further established itself as the first point of contact for health concerns.
  • Mediservice saw excellent growth thanks to new medications for rare diseases combined with the growing demand for home care services.
  • Online sales of Amavita and Sun Store grew by 50%.
  • The linking of online and offline offers gained further momentum, for example with the online booking function for testing and vaccination services.
  • Galexis gained further market shares with new offers for doctors.
  • Acquisitions have allowed Verfora to strengthen its leading position in the Swiss consumer healthcare market.
  • New and existing partnerships with healthcare providers strengthened the offering available to business (B2B) and end customers (B2C).

Key figures for the Galenica Group 2021

(in CHF million)

2021

2020

Change

Segment Products & Care 
- Retail (B2C)
  - Local Pharmacies
  - Pharmacies at Home

1,908.1
1,720.0
1,261.5
458.8

1,683.1
1,517.5
1,162.5
355.2

+13.4%
+13.3%
+8.5%
+29.2%

- Professionals (B2B)
  - Products & Brands
  - Services for Professionals

194.0
131.6
62.4

173.3
111.7
61.5

+11.9%
+17.8%
+1.4%

Segment Logistics & IT
- Wholesale
- Logistics & IT Services

2,831.4
2,728.4
111.9

2,625.1
2,530.2
98.4

+7.9%
+7.8%
+13.7%

Corporate and eliminations

-904.8

-828.4


Galenica Group

3,834.7

3,479.8

+10.2%

EBIT adjustiert1)
Segment Products & Care1)
Segment Logistics & IT1)


154.5
61.0


124.2
45.2


24.4%
35.2%

Corporate and eliminations
Galenica Group1)

-2.4
213.1

-0.8
168.6


26.4%

Net profit adjusted1)

174.8

138.0

26.7%

1) Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the Annual report 2021)

Detailed information in the Annual report 2021

Other press releases

Contact

Galenica Ltd.

Media
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 17
Mobile +41 79 371 77 24
Fax +41 58 852 85 58

Contact

Galenica Ltd.

Investors
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 29
Fax +41 58 852 85 35